Physician profile
Shefali Gupta
NPI 1902927981
$3,772.34
in general payments reported to CMS, 2019-2025
29 companies · $1,245 in 2025
The $1,245 reported for 2025 was more than what 83% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $738 · 2020: $139 · 2021: $403 · 2022: $387 · 2023: $245 · 2024: $615 · 2025: $1,245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,068 · Education: $37.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,067.71 |
| Education | $37.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $496.64 | 2019-2025 | Tavneos, Krystexxa |
| Otsuka America Pharmaceutical, INC. | $472.07 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $346.33 | 2019-2025 | Farxiga |
| Akebia Therapeutics INC | $268.96 | 2022-2025 | Vafseo |
| Mallinckrodt Hospital Products INC. | $221.92 | 2020-2025 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $211.30 | 2021-2025 | |
| Travere Therapeutics, INC. | $180.93 | 2023-2025 | Filspari |
| Aurinia Pharma U.S., INC. | $171.00 | 2021-2025 | Lupkynis |
| Horizon Therapeutics Plc | $169.93 | 2019-2023 | Krystexxa |
| Baxter Healthcare | $123.64 | 2024 | |
| Glaxosmithkline, LLC. | $120.00 | 2021-2024 | Benlysta, Jesduvroq |
| Calliditas Therapeutics US INC. | $117.71 | 2022-2025 | Tarpeyo |
| Ardelyx, INC. | $110.58 | 2024-2025 | Ibsrela |
| Vantive US Healthcare LLC | $104.90 | 2025 | |
| Opko Pharmaceuticals, LLC | $102.40 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $89.97 | 2021-2023 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.15 | 2023-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $76.84 | 2024-2025 | |
| Astellas Pharma US INC | $66.69 | 2019 | |
| Alexion Pharmaceuticals, INC. | $42.02 | 2022-2024 | Ultomiris |
| Cormedix INC. | $28.16 | 2024 | Defencath |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.46 | 2025 | Jynarque |
| Renalytix Ai, INC. | $23.85 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Ascendis Pharma Endocrinology INC | $22.33 | 2025 | Yorvipath |
| Mallinckrodt Enterprises LLC | $22.16 | 2019 | |
| Genentech USA, INC. | $21.67 | 2019 | |
| Apellis Pharmaceuticals, INC. | $20.00 | 2025 | Empaveli |
| Novo Nordisk INC | $19.99 | 2025 | Wegovy |
| Vifor Pharma, INC. | $16.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shefali Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.